NASDAQ:ACORQ Acorda Therapeutics (ACORQ) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free ACORQ Stock Alerts $0.85 +0.15 (+21.43%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.68▼$0.8950-Day Range N/A52-Week Range$0.25▼$24.20Volume19,022 shsAverage Volume109,419 shsMarket Capitalization$1.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsSocial Media Get Acorda Therapeutics alerts: Email Address Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Acorda TherapeuticsAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.Read More ACORQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACORQ Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive ACORQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/01/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ACORQ CUSIPN/A CIK1008848 Webwww.acorda.com Phone914-347-4300Fax914-347-4560Employees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($203.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-252,850,000.00 Net Margins-214.95% Pretax Margin-251.65% Return on Equity-2,206.93% Return on Assets-83.28% Debt Debt-to-Equity Ratio3.07 Current Ratio0.33 Quick Ratio0.26 Sales & Book Value Annual Sales$117.63 million Price / Sales0.01 Cash Flow$44.50 per share Price / Cash Flow0.02 Book Value($127.17) per share Price / Book-0.01Miscellaneous Outstanding Shares1,240,000Free Float1,210,000Market Cap$1.10 million OptionableN/A Beta1.40 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Ron Cohen M.D. (Age 68)Founder, CEO, President & Director Comp: $984.15kMr. Michael A. Gesser M.B.A. (Age 61)Chief Financial Officer Comp: $459.15kMr. Kerry M. Clem (Age 54)Chief Commercial Officer Comp: $592.23kMr. Robert Morales (Age 56)Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller Ms. Felicia VonellaVice President of Investor RelationsMr. Neil S. Belloff Esq. (Age 64)General Counsel & Corporate Secretary Ms. Tierney SaccavinoExecutive Vice President of Corporate CommunicationsMs. Denise J. DucaExecutive Vice President of Human ResourcesMr. Andrew Mayer J.D.Senior Vice PresidentSofia AliSenior VP of Operations & Strategic PlanningMore ExecutivesKey CompetitorsScinai ImmunotherapeuticsNASDAQ:SCNIAcorda TherapeuticsNASDAQ:ACORTC BiopharmNASDAQ:TCBPSQZ BiotechnologiesNYSE:SQZWindtree TherapeuticsNASDAQ:WINTView All Competitors ACORQ Stock Analysis - Frequently Asked Questions How have ACORQ shares performed in 2024? Acorda Therapeutics' stock was trading at $0.44 at the start of the year. Since then, ACORQ shares have increased by 93.2% and is now trading at $0.85. View the best growth stocks for 2024 here. When is Acorda Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ACORQ earnings forecast. How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics, Inc. (NASDAQ:ACORQ) announced its earnings results on Monday, April, 1st. The company reported ($175.32) earnings per share for the quarter. The business had revenue of $37.99 million for the quarter. Acorda Therapeutics had a negative trailing twelve-month return on equity of 2,206.93% and a negative net margin of 214.95%. How do I buy shares of Acorda Therapeutics? Shares of ACORQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACORQ) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceYour bank is lying to you.MyBankTrackerThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
